Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells 2,000 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Thomas Haughey sold 2,000 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the sale, the director owned 38,878 shares in the company, valued at $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock traded up $0.65 on Wednesday, reaching $81.85. 268,475 shares of the company were exchanged, compared to its average volume of 313,632. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The company’s 50-day moving average is $79.51 and its two-hundred day moving average is $79.39. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of 20.72 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 1-year low of $61.17 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same period in the prior year, the firm earned $1.70 EPS. The business’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on ANIP. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $107.33.

Institutional Trading of ANI Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. KBC Group NV bought a new position in ANI Pharmaceuticals during the 1st quarter valued at $28,000. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals during the 1st quarter valued at $28,000. Hantz Financial Services Inc. boosted its stake in ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals during the 4th quarter valued at $48,000. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals during the 2nd quarter valued at $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.